A lot to digest here on both fronts. Not having the cash flow to pay salary without using convertible notes is not necessarily a sign of toxicity within the OTC, but I agree the situation isn’t ideal.
A company buys their Icarus wings when they get into the OTC market, and some melt. I think it remains to be seen substantively what the outcome will be here. If they can actualize on their purchase orders for the GSA distribution contracts, the convertible notes, while not on the best of terms, are still only in the 20k range per. That really suggests to me they are trying to skirt as low as possible before they get through the List-N very with the EPA.
Again, I agree the situation with Optemus isn’t ideal, and I do wonder if that is a result of less then ideal preliminary consulting. The team seems to have a plan and the contingency at the present for shareholders is their ability to execute the EPA approval and form-10 without taking on excessive convertible debt. The share structure could move to 100m+, and if they end up executing their plans, we would be heading for blue skies regardless.
As I keep preaching, we are ultimately speculative on both sides after a point. This launches or it doesn’t like most everything else on iHub.
Here’s hoping for the best.
Market Data 
Markets 
AI
